

Australia lays focus on targeted treatments for triple negative breast cancer

03 August 2021 | News

BioCurate and Monash University accelerate research into targeted treatments for triple negative breast cancer



The first award under BioCurate's new "Proof of Concept" fund has been granted to Australia's Monash Biomedicine Discovery Institute (BDI). This award will support the key research needed to determine the effectiveness of targeting two proteins that could lead to novel, targeted treatments for triple negative breast cancer (TNBC) and other poor prognosis cancers.

The research, led by Professor Roger Daly, who heads the BDI's cancer program, has already identified two proteins that are required by TNBC cells to grow. These proteins represent potential targets for small molecule drugs that could be used to treat this type of cancer.

"Our aim was to identify new targeted treatments that could avoid the side effects of chemotherapy. To do this we applied a screening approach that characterises cellular proteins that transmit growth regulatory signals in the cancer cell," said Professor Daly.

"Understanding this is important, because now we can identify new targets to go after that may open up new therapies against this devastating disease."

Jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government, BioCurate identifies promising biomedical research discoveries and manages their translation into high quality pre-clinical candidates for novel human therapeutics.